Nevada Accuses Juul of Targeting Youth in Lawsuit

Dec.08.2022
Nevada Accuses Juul of Targeting Youth in Lawsuit
Juul accused of marketing to minors and deceiving consumers on nicotine content in Nevada civil suit.

The Nevada Attorney General's office has accused electronic cigarette manufacturer Juul of following the playbook of "big tobacco companies," attempting to make their products attractive to minors and deceiving consumers about the nicotine content in their devices.


In a civil lawsuit filed on Tuesday, the state claimed that Juul Labs, Inc. of San Francisco has hindered the state government's efforts to ban the sale of most flavored cigarettes and market products to people under the age of 21, which was implemented by Congress in the 1990s and later.


State officials said in the lawsuit, "Thanks to the joint efforts of states, the federal government, public health advocates, and many others, the smoking rates among youth and adults have decreased significantly. Unfortunately, the emergence of e-cigarettes has reversed much of the progress.


The complaint was filed after Nevada had reached an agreement with Juul Labs in September, as one of 32 states to settle with the company for $438 million. Nevada's portion of the settlement amounted to $14.4 million. Juul also agreed to stop advertising its electronic cigarettes to minors and to cease using sponsorships and social media influencers to promote its products.


An appeal has been filed with the Clark County District Court in Las Vegas, requesting a permanent injunction to prevent Juul Labs from engaging in violations of Nevada's Deceptive Trade Practices Act. The appeal also calls for civil penalties to be imposed for each infraction committed by the company and urges consideration for compensation and refunds.


A spokesperson for Juul, Arik Ben-Zvi, said that Nevada's application does not constitute a new complaint against the company, but is related to a multi-state settlement agreement reached in September, which includes Nevada.


He stated, "The terms of the agreement align with our current business practices that were established since the company-wide restructuring in autumn 2019.


The US Food and Drug Administration banned the sale of Juul products in June, but suspended its decision after Juul appealed, awaiting a review of further "scientific" issues.


In a complaint filed this week, officials in Nevada compared the e-cigarette industry to the "big tobacco" companies of the pre-1990s, when companies "realized that increasing cigarette sales depended to a large extent on getting individuals addicted to their products from a young age.


As a result, major tobacco companies have developed a comprehensive plan to attract vulnerable children and entice them to use their products,” the office stated. “They have also spent significant resources to expose young people to tobacco imagery through magazine ads, sporting events, and billboards.


Juul Labs sells electronic cigarettes using its proprietary product called a "pod," which delivers nicotine to the users inhaling the e-cigarette.


The pods of the company contain significantly more nicotine compared to other brands and include "nicotine salts" pioneered by Juul Labs, making the inhalant smoother and less irritating than earlier types of electronic smoking devices, according to national officials.


The Office of the Attorney General stated that the company, in its marketing efforts, misled consumers into believing that its products were either nicotine-free or had a lower nicotine concentration and were a safer alternative to combustible cigarettes.


According to state officials, Juul Labs has been selling its tobacco devices to minors from the beginning and, in fact, "the main driver of its explosive growth is young people adopting its products.


A complaint alleges that the company has focused marketing efforts on Instagram, Twitter, Facebook and other social media channels to target younger users.


2FIRSTS will continue to follow and report on this topic. Further updates will be available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18